Detour On FDA’s “Critical Path:” Safety Issues Divert Agency’s Attention

FDA has revised its timeline for the "Critical Path" drug development initiative to reflect more pressing matters, including drug safety issues, Acting Deputy Commissioner for Operations Janet Woodcock said